These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 4829893)

  • 1. Thalidomide and beyond: some recommendations regarding public policies toward the ethical drug industry.
    Schifrin LG
    Int J Health Serv; 1974; 4(1):147-55. PubMed ID: 4829893
    [No Abstract]   [Full Text] [Related]  

  • 2. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 3. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
    Marsh DA; Hoar ME
    Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A perspective on US drug reimportation.
    Choudhry NK; Detsky AS
    JAMA; 2005 Jan; 293(3):358-62. PubMed ID: 15657329
    [No Abstract]   [Full Text] [Related]  

  • 5. QUAD routes out inferior drugs.
    Can Hosp; 1973 May; 50(5):58-9. PubMed ID: 4779804
    [No Abstract]   [Full Text] [Related]  

  • 6. The 1941 sulfathiazole disaster and the birth of good manufacturing practices.
    Swann JP
    Pharm Hist; 1999; 41(1):16-25. PubMed ID: 11623769
    [No Abstract]   [Full Text] [Related]  

  • 7. The economic wisdom of regulating pharmaceutical "freebies".
    Fisher SH
    Duke Law J; 1991 Feb; (1):206-39. PubMed ID: 10114416
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceutical Greed and Its Consequences.
    Jacobs HE
    Conn Med; 2016 May; 80(5):315-6. PubMed ID: 27328583
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA recognition of first-world drug regulators as means of relieving U.S. drug shortages.
    Hunnisett-Dritz D
    Am J Health Syst Pharm; 2012 Oct; 69(19):1626, 1628. PubMed ID: 22997113
    [No Abstract]   [Full Text] [Related]  

  • 10. Physician-ownership in pharmacies and drug repackagers.
    Hoffer GE
    Inquiry; 1975 Mar; 12(1):26-36. PubMed ID: 123219
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug bioequivalence. Recommendations from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States.
    J Pharmacokinet Biopharm; 1974 Oct; 2(5):433-66. PubMed ID: 4452945
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of generics will mean cost savings.
    Nelson G
    Internist; 1979 May; 20(4):6-8. PubMed ID: 10242132
    [No Abstract]   [Full Text] [Related]  

  • 13. MAC--a cutting tool for federal reimbursements on prescription drugs?
    Hirsh HL
    J Leg Med (N Y); 1976 Feb; 4(2):31-3. PubMed ID: 1082483
    [No Abstract]   [Full Text] [Related]  

  • 14. The generic prescribing issue.
    Brater DC; Pettinger WA
    Ann Intern Med; 1980 Mar; 92(3):426-7. PubMed ID: 7356238
    [No Abstract]   [Full Text] [Related]  

  • 15. The pharmacist's role in product selection.
    J Am Pharm Assoc; 1971 Apr; 11(4):181-99. PubMed ID: 5170866
    [No Abstract]   [Full Text] [Related]  

  • 16. The mail-order prescription drug industry.
    Wertheimer AI; Knoben JE
    Health Serv Rep; 1973 Nov; 88(9):852-6. PubMed ID: 4586284
    [No Abstract]   [Full Text] [Related]  

  • 17. New York State and drug lists: a history of confusion.
    Stetler CJ
    Med Mark Media; 1978 Sep; 13(9):36, 38, 40 passim. PubMed ID: 10316687
    [No Abstract]   [Full Text] [Related]  

  • 18. Thalidomide back--under strict control.
    Marwick C
    JAMA; 1997 Oct; 278(14):1135-7. PubMed ID: 9326459
    [No Abstract]   [Full Text] [Related]  

  • 19. Generic vs. brand name drugs--quality, not cost, is key issue.
    Stetler CJ
    Internist; 1979 May; 20(4):9-10, 12. PubMed ID: 10242133
    [No Abstract]   [Full Text] [Related]  

  • 20. Caveat emptor: regulating the online medicine man in the new frontier.
    Stolfi P
    J Contemp Health Law Policy; 2000; 17(1):377-401. PubMed ID: 11216344
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.